Loading...
Loading...
Tuesday, Merck & Co Inc MRK released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC) . The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, Keytruda demonstrated a statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. Related: Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate – A Setback in High-Risk Melanoma Treatment . “This is a significant milestone, as it is the first time an immunotherapy-based regimen has demonstrated a statistically significant overall survival benefit compared to chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer,” said Dr.
Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, KEYNOTE-671 in non-small cell lung cancer, and KEYNOTE-564 in renal cell carcinoma. Earlier this month, Merck’s Phase 3 KEYNOTE-B21 trial of Keytruda in combination with chemotherapy as adjuvant treatment, with or without radi.
